It is trading at $7.90 significantly above $6.99, the 50 day moving average and quite a bit higher than the 200 day moving average of $6.49. The 50 day moving average went up by +13.08% whereas the 200 day average was up by +21.70%. Trading was light with 6,666 shares changing hands by the end of trading on Tuesday. Volume was down 10.31% under the stocks average daily volume.
Traders are a little more bearish on ImmuCell Corporation of late at least if you consider the increase in short interest. The firm realized a rise in short interest between September 29, 2017 and October 13, 2017 of 42.94%. Short interest grew from 10,691 to 15,282 over that timeframe. The short-interest ratio decreased to 2.0 and the percentage of shorted shares is 0.00% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (ICCC). Perritt Capital Management Inc augmented its ownership by buying 7,427 shares an increase of 6.0% from 03/31/2017 to 06/30/2017. Perritt Capital Management Inc owns 130,941 shares with a value of $960,000. The total value of its holdings increased 40.6%. As of quarter end Healthinvest Partners Ab had bought 13,810 shares growing its holdings by 8.2%. The value of the investment in (ICCC) went from $931,000 to $1,335,000 increasing 43.4% for the reporting period.
Tower Research Capital LLC (trc) reduced its position by shedding 478 shares a decrease of 89.0% in the quarter. Tower Research Capital LLC (trc) controls 59 shares worth $0. The value of the position overall is down by 100.0%. As of the end of the quarter Ubs Group Ag had acquired a total of 1,143 shares growing its stake by 757.0%. The value of the total investment in ImmuCell Corporation increased from $1,000 to $9,000 a change of $8,000 quarter to quarter.
The company’s P/E ratio is 90.80 and market capitalization is 39.88M.
ImmuCell Corporation, launched on February 9, 1987, is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Business’s lead product, First Defense, is manufactured from cows’ colostrum (the milk that a cow produces immediately after giving birth) utilizing its vaccine and milk protein purification technologies. The Business’s Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. The Company also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. The Business’s product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows..